Taysha Gene Therapies holds 2024 annual meeting; directors elected and auditor ratified

Taysha Gene Therapies, Inc.

Shareholders elect Sean Stalfort and Alison Long as directors until 2027.
Deloitte & Touche LLP ratified as independent auditor for FY2024.
Approximately 80% of outstanding shares (149.6M of 187M) were represented at the meeting.
Director votes: Stalfort 131.8M for, 287.6K withheld; Long 132.0M for, 77.5K withheld.
Auditor ratification: 149.5M for, 60.4K against, 100.5K abstained; no broker non-votes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.